October 9, 2007 – Medtronic Inc. today announced that it has begun enrolling in the PRECEDE-HF clinical trial that will evaluate Medtronic’s proprietary Cardiac Compass and OptiVol Fluid Status Monitoring features to determine whether cardiac trend data may help physicians prevent heart failure hospitalizations or deaths compared to standard clinical assessment alone.

October 9, 2007 - Ascent Healthcare Solutions announced that the FDA has cleared two Ascent 510(k) submissions to reprocess specific Medtronic and Guidant cardiac stabilization and positioner devices, for use in in Off-Pump Coronary Artery Bypass (OPCAB) procedures.

The Medtronic models include the Octopus Evolution Tissue Stabilizer (as well as the other predecessor Octopus models), Starfish and Urchin Heart Positioners. Guidant models covered under this clearance include the complete line of vacuum and mechanical systems: Xpose, Ultima and Acrobat systems.

October 9, 2007 - Medtronic Inc. will provide a synopsis of clinical data on the Endeavor Drug Eluting Coronary Stent to be presented to an FDA Advisory Panel on October 10, 2007, which will consider whether to recommend approval of the device to the FDA.

Medtronic will submit a pooled data analysis of the major trials encompassing the ENDEAVOR clinical program as well as newly released nine-month results from the ENDEAVOR IV clinical trial. The Panel's recommendation will be subject to FDA approval.

October 9, 2007 - Luna Innovations Inc. has entered into a joint marketing alliance agreement with Terumo Cardiovascular Systems Corp. (Terumo CVS), in which Luna and Terumo CVS will market Luna’s EDAC (Emboli Detection and Classification) Quantifier, as part of Luna's strategy to expand its presence in the U.S.